Attached files

file filename
8-K - 8-K - WATERS CORP /DE/d95376d8k.htm

Exhibit 99.1

For Immediate Release

Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448

Waters Corporation (NYSE: WAT) Reports Third Quarter 2020 Financial Results

 

   

Sales of $594 million grew 3% as reported and 2% in constant currency

 

   

Year-over-year sales increase driven by pharmaceutical and industrial end markets

 

   

Growth in the U.S., Europe, and China, partially offset by declines in other areas

 

   

Recurring revenue grew 5% in constant currency and instrument sales stabilized

 

   

GAAP EPS of $2.03; non-GAAP EPS of $2.16, a 1% increase from prior year

 

   

Strong adjusted free cash flow of $190 million, a 53% increase from prior year

Milford, Mass., October 27, 2020 - Waters Corporation (NYSE: WAT) today announced third quarter 2020 sales of $594 million, a 3% increase as reported, compared to sales of $577 million for the third quarter of 2019. Foreign currency translation benefitted sales growth by approximately 1% for the quarter.

On a GAAP basis, diluted earnings per share (EPS) for the third quarter of 2020 decreased to $2.03, compared to $2.07 for the third quarter of 2019. On a non-GAAP basis, EPS increased to $2.16, compared to $2.13 in the third quarter of 2019. A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company’s website at http://www.waters.com under the caption “Investors.”

On a GAAP basis, net cash provided by operating activities was $173 million for the third quarter of 2020, compared to $148 million for the third quarter of 2019. On a non-GAAP basis, adjusted free cash flow for the third quarter of 2020 was $190 million versus $124 million for the third quarter of 2019.

For the first nine months of 2020, the Company’s sales were $1,579 million, a decrease of 7% as reported, compared to sales of $1,690 million for the first nine months of 2019. Foreign currency translation negatively impacted sales growth by approximately 1% for the first nine months of 2020.

On a GAAP basis, EPS for the first nine months of 2020 decreased to $4.86, compared to $5.63 for the first nine months of 2019. On a non-GAAP basis, EPS decreased to $5.41, compared to $5.85 in the first nine months of 2019. The decrease in both GAAP and non-GAAP EPS can be primarily attributed to the decline in sales volumes.

On a GAAP basis, net cash provided by operating activities was $523 million for the first nine months of 2020, compared to $451 million for the first nine months of 2019. On a non-GAAP basis, adjusted free cash flow for the first nine months of 2020 was $486 million versus $418 million for the first nine months of 2019.

“We are pleased with our solid financial results in the third quarter, which were driven by growth across geographies, while we remain cognizant of the ongoing variability we expect to face in our


end markets during the fourth quarter,” commented Udit Batra, President and Chief Executive Officer of Waters Corporation. “Since joining the Company, I have been working diligently to assess Waters’ overall positioning and to identify key areas in need of improvement. I believe that Waters has established a solid foundation for growth and that we must now turn our focus to improving the consistency of our commercial execution and product development efforts. We will move swiftly, but deliberately, to reinvigorate our business and address those areas in which Waters has underperformed.”

Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis and are the same as the sales growth and decline percentages presented on a constant-currency basis as compared with the same period in the prior year, each of which is detailed in the reconciliation of sales growth rates to constant-currency growth rates in the tables below.

During the third quarter of 2020, sales into the pharmaceutical market increased 5% as reported and 4% in constant currency, sales into the industrial market increased 5% as reported and 3% in constant currency, and sales into the academic and governmental markets declined 8% as reported and 7% in constant currency. For the first nine months of 2020, sales into the pharmaceutical market declined 5% as reported and 4% in constant currency, sales into the industrial market declined 6% as reported and in constant currency, and sales into the academic and governmental markets declined 17% as reported and 16% in constant currency.

During the third quarter, recurring revenues, which represent the combination of service and precision chemistries revenues, increased 6% as reported and 5% in constant currency, while instrument system sales declined 1% as reported and in constant currency. For the first nine months of 2020, recurring revenues were flat as reported and increased 1% in constant currency, while instrument system sales declined 15% as reported and 14% in constant currency.

Geographically, sales in Asia during the quarter declined 1% as reported and were flat in constant currency, sales in the Americas increased 2% (with U.S. sales growing 5%), and sales in Europe increased 11% as reported and 5% in constant currency. For the first nine months of 2020, sales in Asia declined 11% as reported and 10% in constant currency, sales in the Americas declined 7% (with U.S. sales declining 5%), and sales in Europe were flat as reported and in constant currency.

Conference Call

Waters Corporation will webcast its third quarter 2020 financial results conference call today, October 27, 2020 at 8:00 a.m. Eastern Time. To listen to the call, please visit www.waters.com, choose “Investors” and click on the “Live Webcast.” A replay will be available through November 3, 2020 at midnight Eastern Time on the same website by webcast and also by phone at 800-395-6236.

About Waters Corporation

Waters Corporation (NYSE: WAT), the “world’s” leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With more than 7,000 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. For more information, visit www.waters.com.


Non-GAAP Financial Measures

This press release contains financial measures, such as constant-currency growth rate, adjusted operating income, adjusted net income, adjusted earnings per diluted share and free cash flow, among others, which are considered “non-GAAP” financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

Cautionary Statement

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “feels”, “believes”, “anticipates”, “plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects” and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, risks related to the effects of the ongoing COVID-19 pandemic on our business, financial condition, results of operations and prospects, including: portions of our global workforce being unable to work fully and/or effectively due to working remotely, illness, quarantines, government actions, facility closures or other reasons related to the pandemic, increased risks of cyber attacks resulting from our temporary remote working model, disruptions in our manufacturing capabilities or to our supply chain, volatility and uncertainty in global capital markets limiting our ability to access capital, customers being unable to make timely payments for purchases and volatility in demand for our products; foreign exchange rate fluctuations potentially affecting translation of the Company’s future non-U.S. operating results; the impact on demand for the Company’s products among the Company’s various market sectors or geographies from economic, sovereign and political uncertainties, particularly regarding the effect of new or proposed tariff or trade regulations or changes in the interpretation or enforcement of existing regulations; the effect on


the Company’s financial results from the United Kingdom exiting the European Union; fluctuations in expenditures by the Company’s customers, in particular large pharmaceutical companies; introduction of competing products by other companies and loss of market share; pressures on prices from competitors and/or customers; regulatory, economic and competitive obstacles to new product introductions; other changes in demand for the Company’s products from the effect of mergers and acquisitions by the Company’s customers; increased regulatory burdens as the Company’s business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others; shifts in taxable income in jurisdictions with different effective tax rates; the outcome of tax examinations or changes in respective country legislation affecting the Company’s effective tax rate; the effect of the adoption of new accounting standards; the ability to access capital, maintain liquidity and service the Company’s debt in volatile market conditions, particularly in the U.S., as a large portion of the Company’s cash is held and operating cash flows are generated outside the U.S.; environmental and logistical obstacles affecting the distribution of products and risks associated with lawsuits and other legal actions, particularly involving claims for infringement of patents and other intellectual property rights. Such factors and others are discussed more fully in the sections entitled “Forward-Looking Statements” and “Risk Factors” of the Company’s annual report on Form 10-K for the year ended December 31, 2019, as well as in the sections entitled “Special Note Regarding Forward-Looking Statements” and “Risk Factors” of the Company’s quarterly report on Form 10-Q for the quarterly periods ended March 28, 2020 and June 27, 2020, each as filed with the Securities and Exchange Commission (“SEC”), which discussions are incorporated by reference in this release, as updated by the Company’s future filings with the SEC. The forward-looking statements included in this release represent the Company’s estimates or views as of the date of this release and should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.


Waters Corporation and Subsidiaries

Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

 

     Three Months Ended     Nine Months Ended  
     September 26,
2020
    September 28,
2019
    September 26,
2020
    September 28,
2019
 

Net sales

   $ 593,784     $ 577,278     $ 1,578,707     $ 1,690,302  

Costs and operating expenses:

        

Cost of sales

     262,342       241,055       686,120       711,632  

Selling and administrative expenses

     135,430       126,036       400,614       393,583  

Research and development expenses

     34,971       34,333       101,115       105,883  

Purchased intangibles amortization

     2,657       2,619       7,900       7,164  

Litigation provision

     —         —         1,180       —    

Operating income

     158,384       173,235       381,778       472,040  

Other expense

     (1,039     (496     (2,149     (1,363

Interest expense, net

     (6,908     (8,001     (25,966     (16,826

Income from operations before income taxes

     150,437       164,738       353,663       453,851  

Provision for income taxes(1)

     23,668       26,605       50,403       62,322  

Net income

   $ 126,769     $ 138,133     $ 303,260     $ 391,529  

Net income per basic common share

   $ 2.04     $ 2.09     $ 4.89     $ 5.68  

Weighted-average number of basic common shares

     62,002       66,226       62,057       68,952  

Net income per diluted common share

   $ 2.03     $ 2.07     $ 4.86     $ 5.63  

Weighted-average number of diluted common shares and equivalents

     62,303       66,768       62,371       69,533  

 

(1)

The provision for income taxes for the nine months ended September 28, 2019 included a $3 million benefit related to the tax on the change in foreign currency exchange rates on the earnings taxed in December 31, 2017 under the Tax Cuts and Jobs Act and the subsequent finalization of the tax regulations during the first quarter of 2019. The difference is due to the change from the foreign currency exchange rates required by the U.S. Department of the Treasury on December 31, 2017 to the foreign currency exchange rates on either the date of distribution of assets into the U.S. or the foreign currency exchange rates as of September 28, 2019.


Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP

Net Sales by Operating Segment, Products & Services, Geography and Markets

Three Months Ended September 26, 2020 and September 28, 2019

(In thousands)

 

                         Current        
                         Period     Constant  
     Three Months Ended      Percent     Currency     Currency  
     September 26, 2020      September 28, 2019      Change     Impact     Growth Rate (a)  

NET SALES - OPERATING SEGMENT

            

Waters

   $ 533,466      $ 512,146        4   $ 4,759       3

TA

     60,318        65,132        (7 %)      532       (8 %) 
  

 

 

    

 

 

      

 

 

   

Total

   $ 593,784      $ 577,278        3   $ 5,291       2
  

 

 

    

 

 

      

 

 

   

NET SALES - PRODUCTS & SERVICES

            

Instruments

   $ 268,064      $ 270,317        (1 %)    $ 1,692       (1 %) 

Service

     217,545        206,705        5     2,230       4

Chemistry

     108,175        100,256        8     1,369       7
  

 

 

    

 

 

      

 

 

   

Total Recurring

     325,720        306,961        6     3,599       5
  

 

 

    

 

 

      

 

 

   

Total

   $ 593,784      $ 577,278        3   $ 5,291       2
  

 

 

    

 

 

      

 

 

   

NET SALES - GEOGRAPHY

            

Asia

   $ 236,182      $ 237,775        (1 %)    $ (2,254     —    

Americas

     199,447        196,458        2     (106     2

Europe

     158,155        143,045        11     7,651       5
  

 

 

    

 

 

      

 

 

   

Total

   $ 593,784      $ 577,278        3   $ 5,291       2
  

 

 

    

 

 

      

 

 

   

NET SALES - MARKETS

            

Pharmaceutical

   $ 343,001      $ 328,227        5   $ 2,537       4

Industrial

     179,128        171,352        5     3,345       3

Academic & Governmental

     71,655        77,699        (8 %)      (591     (7 %) 
  

 

 

    

 

 

      

 

 

   

Total

   $ 593,784      $ 577,278        3   $ 5,291       2
  

 

 

    

 

 

      

 

 

   

NET SALES - EXCLUDING CHINA

            

Total Net Sales

   $ 593,784      $ 577,278        3   $ 5,291       2

China Net Sales

     115,666        111,657        4     951       3
  

 

 

    

 

 

      

 

 

   

Total Net Sales Excluding China

   $ 478,118      $ 465,621        3   $ 4,340       2
  

 

 

    

 

 

      

 

 

   

 

(a)

The Company believes that referring to comparable constant-currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation’s net sales. Constant-currency growth rate, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.


Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP

Net Sales by Operating Segment, Products & Services, Geography and Markets

Nine Months Ended September 26, 2020 and September 28, 2019

(In thousands)

 

                         Current        
                         Period     Constant  
     Nine Months Ended      Percent     Currency     Currency  
     September 26, 2020      September 28, 2019      Change     Impact     Growth Rate (a)  

NET SALES - OPERATING SEGMENT

            

Waters

   $ 1,413,386      $ 1,503,177        (6 %)    $ (5,001     (6 %) 

TA

     165,321        187,125        (12 %)      (613     (11 %) 
  

 

 

    

 

 

      

 

 

   

Total

   $ 1,578,707      $ 1,690,302        (7 %)    $ (5,614     (6 %) 
  

 

 

    

 

 

      

 

 

   

NET SALES - PRODUCTS & SERVICES

            

Instruments

   $ 664,817      $ 778,540        (15 %)    $ (2,187     (14 %) 

Service

     613,365        611,961        —         (2,916     1

Chemistry

     300,525        299,801        —         (511     —    
  

 

 

    

 

 

      

 

 

   

Total Recurring

     913,890        911,762        —         (3,427     1
  

 

 

    

 

 

      

 

 

   

Total

   $ 1,578,707      $ 1,690,302        (7 %)    $ (5,614     (6 %) 
  

 

 

    

 

 

      

 

 

   

NET SALES - GEOGRAPHY

            

Asia

   $ 603,471      $ 677,122        (11 %)    $ (6,801     (10 %) 

Americas

     546,405        585,101        (7 %)      (35     (7 %) 

Europe

     428,831        428,079        —         1,222       —    
  

 

 

    

 

 

      

 

 

   

Total

   $ 1,578,707      $ 1,690,302        (7 %)    $ (5,614     (6 %) 
  

 

 

    

 

 

      

 

 

   

NET SALES - MARKETS

            

Pharmaceutical

   $ 926,582      $ 972,884        (5 %)    $ (4,937     (4 %) 

Industrial

     474,592        502,679        (6 %)      1,410       (6 %) 

Academic & Governmental

     177,533        214,739        (17 %)      (2,087     (16 %) 
  

 

 

    

 

 

      

 

 

   

Total

   $ 1,578,707      $ 1,690,302        (7 %)    $ (5,614     (6 %) 
  

 

 

    

 

 

      

 

 

   

NET SALES - EXCLUDING CHINA

            

Total Net Sales

   $ 1,578,707      $ 1,690,302        (7 %)    $ (5,614     (6 %) 

China Net Sales

     252,713        314,544        (20 %)      (1,897     (19 %) 
  

 

 

    

 

 

      

 

 

   

Total Net Sales Excluding China

   $ 1,325,994      $ 1,375,758        (4 %)    $ (3,717     (3 %) 
  

 

 

    

 

 

      

 

 

   

 

(a)

The Company believes that referring to comparable constant-currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation’s net sales. Constant-currency growth rate, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.


Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP Financials

Three & Nine Months Ended September 26, 2020 and September 28, 2019

(In thousands, except per share data)

 

    Selling &
Administrative
Expenses(a)
    Operating
Income
    Operating
Income
Percentage
    Other
Expense
    Income from
Operations
before
Income
Taxes
    Provision for
Income
Taxes
    Net
Income
    Diluted
Earnings
per Share
 

Quarter Ended September 26, 2020

               

GAAP

  $ 138,087     $ 158,384       26.7   $ (1,039   $ 150,437     $ 23,668     $ 126,769     $ 2.03  

Adjustments:

               

Purchased intangibles amortization (b)

    (2,657     2,657       0.4     —         2,657       524       2,133       0.03  

Restructuring costs and certain other items (c)

    (6,771     6,771       1.1     —         6,771       1,692       5,079       0.08  

Certain income tax items (d)

    —         —         —         —         —         (685     685       0.01  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted Non-GAAP

  $ 128,659     $ 167,812       28.3   $ (1,039   $ 159,865     $ 25,199     $ 134,666     $ 2.16  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Quarter Ended September 28, 2019

               

GAAP

  $ 128,655     $ 173,235       30.0   $ (496   $ 164,738     $ 26,605     $ 138,133     $ 2.07  

Adjustments:

               

Purchased intangibles amortization (b)

    (2,619     2,619       0.5     —         2,619       535       2,084       0.03  

Restructuring costs and certain other items (c)

    (1,596     1,596       0.3     —         1,596       350       1,246       0.02  

Certain income tax items (d)

    —         —         —         —         —         (600     600       0.01  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted Non-GAAP

  $ 124,440     $ 177,450       30.7   $ (496   $ 168,953     $ 26,890     $ 142,063     $ 2.13  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Nine Months Ended September 26, 2020

               

GAAP

  $ 409,694     $ 381,778       24.2   $ (2,149   $ 353,663     $ 50,403     $ 303,260     $ 4.86  

Adjustments:

               

Purchased intangibles amortization (b)

    (7,900     7,900       0.5     —         7,900       1,561       6,339       0.10  

Restructuring costs and certain other items (c)

    (33,054     33,054       2.1     (461     32,593       7,373       25,220       0.40  

Litigation provisions (e)

    (1,180     1,180       0.1     —         1,180       283       897       0.01  

Certain income tax items (d)

    —         —         —         —         —         (1,567     1,567       0.03  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted Non-GAAP

  $ 367,560     $ 423,912       26.9   $ (2,610   $ 395,336     $ 58,053     $ 337,283     $ 5.41  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Nine Months Ended September 28, 2019

               

GAAP

  $ 400,747     $ 472,040       27.9   $ (1,363   $ 453,851     $ 62,322     $ 391,529     $ 5.63  

Adjustments:

               

Purchased intangibles amortization (b)

    (7,164     7,164       0.4     —         7,164       1,520       5,644       0.08  

Restructuring costs and certain other items (c)

    (14,382     14,382       0.9     —         14,382       3,623       10,759       0.15  

Tax reform (f)

    —         —         —         —         —         3,229       (3,229     (0.05

Certain income tax items (d)

    —         —         —         —         —         (1,908     1,908       0.03  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted Non-GAAP

  $ 379,201     $ 493,586       29.2   $ (1,363   $ 475,397     $ 68,786     $ 406,611     $ 5.85  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(a)

Selling & administrative expenses include purchased intangibles amortization and litigation provisions.

(b)

The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time.

(c)

Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations and reduce overhead and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company.

(d)

Certain income tax items were excluded as these non-cash expenses and benefits represent updates in management’s assessment of ongoing examinations or other tax items that are not indicative of the Company’s normal or future income tax expense.

(e)

Litigation provisions were excluded as these items are isolated, unpredictable and not expected to recur regularly.

(f)

The provision for income taxes for nine months ended September 28, 2019 included a $3 million benefit related to the tax on the change in foreign currency exchange rates on the earnings taxed in December 31, 2017 under the Tax Cuts and Jobs Act and the subsequent finalization of the tax regulations during the first quarter of 2019. The difference is due to the change from the foreign currency exchange rates required by the U.S. Department of the Treasury on December 31, 2017 to the foreign currency exchange rates on either the date of distribution of assets into the U.S. or the foreign currency exchange rates as of September 28, 2019.


Waters Corporation and Subsidiaries

Preliminary Condensed Unclassified Consolidated Balance Sheets

(In thousands and unaudited)

 

     September 26, 2020     December 31, 2019  

Cash, cash equivalents and investments

   $ 397,070     $ 337,144  

Accounts receivable

     494,432       587,734  

Inventories

     326,946       320,551  

Property, plant and equipment, net

     469,721       417,342  

Intangible assets, net

     255,168       240,203  

Goodwill

     431,078       356,128  

Other assets

     304,871       297,953  

Total assets

   $ 2,679,286     $ 2,557,055  

Notes payable and debt

   $ 1,571,337     $ 1,681,163  

Other liabilities

     1,149,530       1,092,173  

Total liabilities

     2,720,867       2,773,336  

Total stockholders’ deficit

     (41,581     (216,281

Total liabilities and stockholders’ deficit

   $ 2,679,286     $ 2,557,055  


Waters Corporation and Subsidiaries

Preliminary Condensed Consolidated Statements of Cash Flows

Three and Nine Months Ended September 26, 2020 and September 28, 2019

(In thousands and unaudited)

 

     Three Months Ended     Nine Months Ended  
     September 26, 2020     September 28, 2019     September 26, 2020     September 28, 2019  

Cash flows from operating activities:

        

Net income

   $ 126,769     $ 138,133     $ 303,260     $ 391,529  

Adjustments to reconcile net income to net cash provided by operating activities:

        

Stock-based compensation

     9,593       9,662       27,715       28,917  

Depreciation and amortization

     30,888       26,704       91,091       80,319  

Change in operating assets and liabilities, net

     5,329       (26,110     100,959       (49,573
  

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by operating activities

     172,579       148,389       523,025       451,192  

Cash flows from investing activities:

        

Additions to property, plant, equipment and software capitalization

     (28,311     (45,017     (125,340     (110,205

Business acquisitions, net of cash acquired

     —         —         (76,664     —    

Investment in unaffiliated companies

     (500     (2,500     (3,850     (7,250

Net change in investments

     (5,415     87,895       (20,707     942,896  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net cash (used in) provided by investing activities

     (34,226     40,378       (226,561     825,441  

Cash flows from financing activities:

        

Net change in debt

     (125,000     206,830       (110,366     206,948  

Proceeds from stock plans

     13,682       4,182       28,421       34,311  

Purchases of treasury shares

     (56     (580,065     (196,353     (1,909,700

Other cash flow from financing activities, net

     2,772       2,246       10,330       6,900  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in financing activities

     (108,602     (366,807     (267,968     (1,661,541

Effect of exchange rate changes on cash and cash equivalents

     6,147       (5,309     10,723       (6,723
  

 

 

   

 

 

   

 

 

   

 

 

 

Increase (decrease) in cash and cash equivalents

     35,898       (183,349     39,219       (391,631

Cash and cash equivalents at beginning of period

     339,036       587,998       335,715       796,280  
  

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 374,934     $ 404,649     $ 374,934     $ 404,649  
  

 

 

   

 

 

   

 

 

   

 

 

 

 

Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a)

 

 

Net cash provided by operating activities - GAAP

   $ 172,579     $ 148,389     $ 523,025     $ 451,192  

Adjustments:

        

Additions to property, plant, equipment and software capitalization

     (28,311     (45,017     (125,340     (110,205

Tax reform payments

     38,454       —         38,454       29,109  

Major facility renovations

     7,253       21,073       50,320       48,348  
  

 

 

   

 

 

   

 

 

   

 

 

 

Free Cash Flow - Adjusted Non-GAAP

   $ 189,975     $ 124,445     $ 486,459     $ 418,444  
  

 

 

   

 

 

   

 

 

   

 

 

 

 

(a)

The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies.